Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.

Locally Advanced / Metastatic Solid Tumors

Crescent Biopharma, Inc.290 participantsStarted Feb 2026

Denver, Colorado, United States • Orlando, Florida, United States • Sarasota, Florida, United States +7 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors